Screener
First Tracks Biotherapeutics Inc TRAX Operating Income
Operating Income at other companies
Where this comes from
Reported directly by First Tracks Biotherapeutics Inc in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: First Tracks Biotherapeutics Inc’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224190
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $33,955 | $41,465 |
| General and administrative | 18,856 | 9,815 |
| Total operating expenses | 52,811 | 51,280 |
| Loss from operations | (52,811) | (51,280) |
| Other income (expense), net: | ||
| Interest income | 2,328 | 4,091 |
| Other expense, net | (1) | (7) |
| Total other income, net | 2,327 | 4,084 |
Item 1. Combined Financial Statements.
FAQ
- What is First Tracks Biotherapeutics Inc's operating income?
- First Tracks Biotherapeutics Inc (TRAX) reported operating income of -$52.81M in Q1 2026.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about First Tracks Biotherapeutics Inc's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude